EssilorLuxottica SA (EL) AI Stock Analysis

• Market Cap: €101.34B
• Dividend Yield: 1.46%
• Average Volume (3M): 420.79K
• Price to Earnings (P/E): 44.7
• Beta (1Y): 0.94
• Revenue Growth: 5.45%
• EPS Growth: 2.86%
• Country: FR
• Employees: 153,498
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 2.91
• Shares Outstanding: 463,289,580
• 10 Day Avg. Volume: 450,041
• 30 Day Avg. Volume: 420,785
• PEG Ratio: -17.39
• Price to Book (P/B): 3.19
• Price to Sales (P/S): 4.35
• P/FCF Ratio: 32.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €326.67
• Price Target Upside: 45.06% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): 7.44
• Revenue Forecast (FY): €31.19B

• Rating: 61 Neutral
• Price Target: €273.00 ▲(21.23% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is primarily supported by solid financial performance (steady growth, high gross profitability, and improving 2025 free cash flow), but is held back by weaker technical momentum (below key moving averages and negative MACD) and a rich valuation (high P/E with only a modest dividend yield).

Positive Factors

Integrated business model & strong brands

Vertical integration across lenses, frames, manufacturing and retail creates a durable competitive advantage. Iconic brands plus retail and licensing channels diversify revenue, protect margins versus pure-play competitors, and support sustained pricing power and innovation investment over multiple years.

Steady revenue growth and high gross margins

Consistent mid-single-digit revenue growth and gross margins around the low-60s indicate resilient demand and product mix quality. This durable top-line momentum and high gross profitability underpin predictable operating cash flows and provide scope for R&D, premium positioning, and long-term margin maintenance.

Improving free cash flow trend

Rising operating cash flow and a marked improvement in free cash flow in 2025 strengthen the firm's ability to fund capex, brand investments and shareholder returns. Improved cash generation enhances financial flexibility and supports deleveraging or targeted M&A over the medium term.

Negative Factors

Notable debt increase in 2025

A step-up in debt weakens the balance-sheet trajectory and reduces financial flexibility. Higher leverage increases interest expense sensitivity, limits optionality for acquisitions or buybacks, and raises refinancing risk if cash generation falters amid cyclical pressures or higher rates.

Eased operating and EBITDA margins

A decline in operating and EBITDA margins suggests margin pressure from cost inflation, investment spending, or competitive pricing. If sustained, weaker operating profitability can compress return on capital, constrain reinvestment capacity, and reduce the buffer against economic downturns.

Subpar cash conversion and uneven FCF

Free cash flow materially below net income signals working-capital or investment drains that limit cash available for shareholders or debt paydown. Uneven FCF across cycles increases sensitivity to operational swings and makes long-term planning for dividends or M&A more uncertain.

EssilorLuxottica SA Business Overview & Revenue Model

Company Description

EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, Latin America, Asia, Oceania, and Africa. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions; and Transitions Signature Gen 8 photochromic lens, as well as develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses and Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, and SolarShield brands; Reebok, Steve Madden, Betsey Johnson, Nine West, Dockers, French Connection, Ironman, Rawlings, Bodyglove, Panama Jack, Marvel, and Disney; Bolon, Molsion, Qina, and Prosun brands; and Mujosh and Aojo brands. It has a network of 490 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.

How the Company Makes Money

EssilorLuxottica generates revenue through various streams including the sale of prescription lenses, which are critical for vision correction, and eyewear sales from its extensive range of branded and private-label products. The company operates a significant retail network encompassing optical shops and e-commerce platforms, which contribute to direct sales. Additionally, partnerships with eye care professionals and optical retailers enhance its distribution capabilities. The company also benefits from licensing agreements for its brands, allowing for additional revenue through royalties. The comprehensive integration of manufacturing, distribution, and retail strengthens its market presence and profitability.

EssilorLuxottica SA Financial Statement Overview

Summary

Strong overall fundamentals with steady 2023–2025 revenue growth and consistently high gross margins. Offsetting factors include softer operating/EBITDA margins in 2025, a notable step-up in debt versus 2024, and cash conversion below net income (FCF ~0.69–0.71x), despite improving free cash flow in 2025.

Income Statement

Revenue has grown steadily from 2023 to 2025 (about 4–5% annual growth), showing resilient demand after the 2020 downturn. Profitability is solid with consistently high gross margin (roughly 61–63%), and operating profitability remains healthy, though it eased in 2025 as operating and EBITDA margins stepped down versus 2024. Net margin is stable around ~8–9% in recent years, indicating dependable earnings power but not strong recent margin expansion.

Balance Sheet

Leverage remains reasonable with debt sitting at roughly one-third to under one-half of equity across the period, supporting balance-sheet flexibility. However, debt increased notably in 2025 versus 2024, which slightly weakens the trajectory even as equity remains large. Returns on equity in 2022–2024 are steady but moderate (around ~6%), suggesting solid stability rather than outsized value creation.

Cash Flow

Cash generation is consistent with operating cash flow rising into 2025 and free cash flow growing strongly in 2025 versus 2024. That said, free cash flow is meaningfully below net income (about 0.69–0.71x recently), indicating some working-capital or investment drag versus accounting earnings. Free cash flow growth has also been uneven over the cycle (declines in 2020 and 2022), though the recent trend is improving.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	28.49B	26.51B	25.39B	24.49B	19.82B
Gross Profit	17.25B	16.81B	16.05B	15.59B	12.28B
EBITDA	6.47B	6.55B	6.18B	6.10B	4.71B
Net Income	2.31B	2.36B	2.29B	2.15B	1.45B
Balance Sheet
Total Assets	63.90B	64.26B	60.52B	60.56B	59.41B
Cash, Cash Equivalents and Short-Term Investments	3.54B	2.25B	2.56B	1.99B	3.33B
Total Debt	17.05B	13.22B	11.66B	12.20B	13.02B
Total Liabilities	24.40B	23.26B	21.63B	22.41B	23.54B
Stockholders Equity	38.89B	40.38B	38.24B	37.45B	35.06B
Cash Flow
Free Cash Flow	3.77B	3.35B	3.33B	3.21B	3.52B
Operating Cash Flow	5.29B	4.87B	4.86B	4.78B	4.54B
Investing Cash Flow	-2.64B	-3.62B	-1.72B	-3.29B	-8.13B
Financing Cash Flow	-971.00M	-1.65B	-2.36B	-2.91B	-1.97B

EssilorLuxottica SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 225.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EL, the sentiment is Negative. The current price of 225.2 is below the 20-day moving average (MA) of 246.54, below the 50-day MA of 260.21, and below the 200-day MA of 268.55, indicating a bearish trend. The MACD of -8.79 indicates Positive momentum. The RSI at 28.96 is Positive, neither overbought nor oversold. The STOCH value of 15.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:EL.

EssilorLuxottica SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMS	76 Outperform	€214.41B	47.49	25.50%	1.24%	10.31%	0.54%
CDI	64 Neutral	€89.63B	20.59	19.54%	2.33%	-3.24%	-21.65%
MC	63 Neutral	€258.74B	24.89	16.88%	2.06%	-3.24%	-21.24%
EL	61 Neutral	€101.34B	44.65	6.19%	1.46%	5.45%	2.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KER	48 Neutral	€33.28B	484.58	4.91%	2.03%	-14.56%	-64.91%